Drug Trial Radar · NCT06131983
Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
60
Planned (sponsor's estimate)
Start
Jun 19, 2024
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Sarepta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of SRP-1001 in participants with facioscapulohumeral muscular dystrophy Type 1 (FSHD1). In Part 1 of the study, participants will receive one dose of SRP-1001 or placebo. In Part 2 of the study, participants will receive 4 doses of SRP-1001 or placebo. Participants who complete Part 1 will have the option to re-screen and re-randomize into Part 2. All participants will undergo pre- and post-dose magnetic imaging resonance (MRI)-guided muscle biopsies (a total of 2 biopsies). Participants who complete Part 1 and enroll in Part 2 will be required to undergo an additional screening biopsy. Participants completing Part 1 or Part 2 may have the option to continue to receive drug in an open-label extension study or may be eligible to participate in later-stage clinical studies.
Conditions
- Muscular Dystrophy, Facioscapulohumeral
Interventions
SRP-1001 for InjectionDrug
Single or multiple doses of SRP-1001 by intravenous (IV) infusion
PlaceboDrug
Calculated volume to match active treatment by IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events Over Time Through End of StudyTime frame: Part 1: Up to Day 90; Part 2: Up to Day 360
Locations
16 sites in 7 countries. Site status is shown where the registry gives one.
Liverpool Hospital
Liverpool, New South Wales, Australia
Wesley Research Institute
Auchenflower, Queensland, Australia
Sunshine Coast University Hospital
Birtinya, Queensland, Australia
Alfred Health
Melbourne, Victoria, Australia
University of Calgary
Calgary, Alberta, Canada
University of Alberta
Edmonton, Alberta, Canada
McGill University
Montreal, Quebec, Canada
Universitätsklinikum München
München, Germany
Neurologische Universitätsklinik Am Rku
Ulm, Germany
Centro Clinico Nemo Milann
Milan, Italy
Fondazione Policlinico Universitario A. Gemelli
Roma, Italy
Centre For Human Drug Research
Leiden, Netherlands
New Zealand Clinical Research
Auckland, New Zealand
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
Hospital Universitari l Politecnic La Fe de Valencia
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.